1st Quarter - Amendment
OREXIGEN THERAPEUTICS, INC. for OREXIGEN THERAPEUTICS, INC.
Client
Income
—
Expenses
$107,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 17, 2012 | $107,000 | Replaced |
| 1st Quarter - Amendment (this page) | May 21, 2012 | $107,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Legislative and regulatory matters related to the Food and Drug Administration (FDA) and the Centers for Medicare and Medicaid Services (CMS) with a focus on the regulation of novel therapeutics for the treatment of obesity.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KEVIN BRENNAN New | — |
| PAUL KIM New | — |
| SUZANNE MARIE MCDONALD | — |
| HEATHER DINEEN TURNER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.